Alivus Life Sciences Takes The Spotlight After 66% YoY Profit Jump in Q4; Announces ₹5 Final Dividend

Synopsis: Alivus Life Sciences Ltd reported a strong performance for Q4 FY26, driven by healthy revenue growth and a sharp improvement in profitability. The company posted a 66 percent year-on-year jump in net profit, while revenue also recorded steady growth during the quarter. 

Alivus Life Sciences Ltd, formerly known as Glenmark Life Sciences, is a leading Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The company caters to regulated and emerging markets globally and has a strong presence across therapeutic segments such as cardiovascular, anti-diabetic, CNS, pain management, and gastrointestinal treatments. 

Alivus Life Sciences Ltd currently has a market capitalization of Rs. 30,326 crore. The stock is trading at Rs. 1,039 per share down by 0.40% compared to its previous close of Rs. 1,044, compared to its 52-week high of Rs. 1,108 and 52-week low of Rs. 630. 

The company has a stock P/E ratio of 48 times, while its ROCE and ROE stand at 4.91 percent and 5.81 percent respectively. Alivus Life Sciences also offers a dividend yield of 1.89 percent, reflecting its continued focus on shareholder returns. 

Alivus Life Sciences reported revenue from operations of Rs. 689 crore in Q4 FY26, registering a growth of around 6 percent on a quarter-on-quarter basis compared to Rs. 673 crore in Q3 FY26. On a year-on-year basis, revenue increased by nearly 6 percent from Rs. 650 crore reported in Q4 FY25. 

The company’s operating profit stood at Rs. 215 crore during the quarter, compared to Rs. 231 crore in the previous quarter and Rs. 198 crore in the same quarter last year. Operating margins remained healthy at 31 percent in Q4 FY26. 

Profit before tax came in at Rs. 216 crore, reflecting a growth of around 9 percent QoQ from Rs. 198 crore reported in Q3 FY26. On a YoY basis, PBT increased by nearly 13 percent from Rs. 191 crore recorded in Q4 FY25. 

Net profit for the quarter stood at Rs. 163 crore, compared to Rs. 150 crore in Q3 FY26 and Rs. 98 crore in Q4 FY25. This represents a growth of around 9 percent sequentially and a sharp 66 percent increase on a year-on-year basis. Earnings per share (EPS) also improved to Rs. 13.25 in Q4 FY26 from Rs. 12.25 in Q3 FY26 and Rs. 11.58 in Q4 FY25.  The Board of Directors recommended a final dividend of Rs. 5 per equity share for the financial year 2025-26. The dividend recommendation is subject to approval from shareholders at the upcoming Annual General Meeting.

India’s pharmaceutical industry continues to witness strong long-term growth supported by rising healthcare demand, increasing exports, and government incentives for domestic manufacturing. According to industry estimates, the Indian pharmaceutical market stood at Rs. 4.71 lakh crore in 2025 and is expected to grow significantly by 2030. 

Government initiatives such as the PLI scheme, increased healthcare spending, and rising global demand for affordable medicines are expected to support the sector further. India also continues to remain one of the world’s largest suppliers of generic medicines and vaccines, strengthening its position as a global pharmaceutical manufacturing hub. 

Alivus Life Sciences delivered a strong Q4 FY26 performance with steady revenue growth and impressive improvement in profitability. The sharp rise in net profit, stable operating margins, and dividend announcement indicate improving operational strength and healthy business momentum. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Alivus Life Sciences Takes The Spotlight After 66% YoY Profit Jump in Q4; Announces ₹5 Final Dividend appeared first on Trade Brains.